A new in-vitro study using cell culture has shown that norepinephrine,
the stress hormone, may cause growth and spread of certain tumour cells by hastening the biochemical signals that stimulate them. This may consequently quicken the progression of certain blood cancers.
The finding, if verified, may suggest a way of slowing the progression and spread of some cancers enough so that conventional chemotherapeutic treatments would have a better chance to work.
The study also showed that stress hormones may play a totally different role in cancer development than researchers had once thought.
We would not be surprised if we see similar effects of norepinephrine on tumor progression in several different forms of cancer, explained Eric Yang, first author of the paper and a research scientist with the Institute for Behavioral Medicine Research (IBMR) at Ohio State University.
The researchers looked at a different type of blood cancer multiple myeloma, focussing on three multiple myeloma tumor cell lines, each representing a different stage in the life of the disease, for their experiments. While all three-tumour cell lines reacted to the presence of norepinephrine, only one, a cell line known as FLAM-76, responded strongly to the hormone.
The fact that this one cell line, of the three multiple myeloma cell lines studied, closely represents the early stages of the tumour, and that this is where we see the biggest effect, is what makes this work more clinically relevant, Yang said.